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Aaron L. Baggish, MD, FACC*
Robert J. Myerburg, MD, FACC*The use of performance-enhancing drugs and sub-
stances, or doping, is one of the most important and
difﬁcult challenges in contemporary sports. Doping
occurs when a prohibited substance or its metabolite
is documented in a bodily specimen or when a pro-
hibited method is used to increase athletic perfor-
mance (1). Most commonly, the substances or
methods used for doping have not been evaluated for
therapeutic use. The abuse of counterfeit or designer
drugs that are not regulated is a particular threat to
the athlete’s health. Doping also threatens theintegrity of sport. The use of artiﬁcial enhancements
to gain an advantage over others in competition is
fundamentally unfair to athletes who train and
compete by the rules.
Athletic governing organizations maintain updated
lists of prohibited substances (2). The prohibition
of these agents is based on preventing an unfair ath-
letic advantage and eliminating the health risks of
doping. Generally, these drugs fall into categories
that include anabolic agents, hormones and related
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2430diuretic agents (1,2). Multiple masking agents are also
prohibited because they are used to hide or prevent
detection of a banned substance (1,2). Drugs used for
enhancement of oxygen transfer, such as erythropoietin,
or techniques of autotransfusion are also prohibited (1,2).
Many drugs and substances considered “recreational”
rather than performance enhancing, including narcotics,
cannabinoids, and alcohol, are also prohibited (1,2).
Of the many adverse effects of performance-enhancing
substances, those that affect the cardiovascular system
are among the most serious and will be the focus of this
document (3). This section also summarizes the best
available, albeit limited, data on the adverse cardiovas-
cular effects of prohibited substances in athletes. In
addition, strategies for effective implementation of anti-
doping programs will be discussed, and speciﬁc recom-
mendations for healthcare professionals will be made. To
ensure harmonized, coordinated, and effective antidop-
ing programs at the international and national level with
regard to detection, deterrence, and prevention of
doping, a World Anti-Doping Code has been accepted by
almost all international athletic organizations (4). Ulti-
mately, all stakeholders, including athletic governing or-
ganizations, athletes, trainers, and physicians, have a
shared responsibility to discourage the use of doping in
sports.
The evidence base for performance-enhancing drugs
and substances is subject to limitations not usually
encountered in the assessment of risk and beneﬁt for
cardiovascular drugs approved by the U.S. Food and Drug
Administration (FDA). Scientiﬁcally designed studies of
efﬁcacy are lacking, and many reports or opinions are
subjective and often speciﬁc to an individual sport. The
application of randomized clinical trials has not been
feasible and in many cases may be considered unethical
because of the listing of the drug or substance on lists of
banned substances (5). Searches of the medical literature
for randomized trials demonstrate very few clinical trials
that evaluated the efﬁcacy and safety of performance-
enhancing drugs or substances. One prospective ran-
domized trial of supraphysiological doses of testosterone
combined with strength training demonstrated an
increased fat-free mass and muscle size and strength in
normal men with this steroid (6). The ClinicalTrials.gov
Web site does not list any currently enrolling trials
when searched under the terms of sports or performance
(7). Because many of the substances in question are
regulated by the FDA as food supplements, claims of
efﬁcacy are not substantiated by randomized clinical
trials.
The evidence base for safety is somewhat more
extensive but is also limited by its observational nature
and the absence of randomized trials with placebo
controls in most cases. Excellent summaries of thedetrimental cardiovascular effects of performance-
enhancing substances have been published (5,8). FDA
efforts are largely directed at individual product recalls
and warning letters for unwarranted claims rather than
published trial data. However, in its ban of ephedra-
containing dietary supplements in the United States in
2004, the FDA based its decision on the principle of
“unreasonable risk,” a risk-beneﬁt analytical method
based on even a small potential for harm in the absence of
any scientiﬁcally reliable support for beneﬁt (9). The FDA
avoided the principle of “signiﬁcant risk,” which would
have required a higher level of scientiﬁc reliability of
speciﬁc risk than was available (9). Gaps in the evidence
base may continue to expand. The number of
performance-enhancing substances available to athletes
continues to increase, and the substances are readily
available via the Internet. Large numbers of youth are
being prescribed stimulant drugs to treat attention-deﬁcit
hyperactivity disorder, with a prevalence estimated to be
as high as 10% of the relevant age group (10). Participation
of these patients in competitive sports will require
assessment of the risk and beneﬁt. Finally, athletes will
continue to explore new substances to enhance perfor-
mance, without the beneﬁt of adequate trials of efﬁcacy
or measures of safety published in the medical literature.
The term antidoping program refers to any organized
system designed to prevent the use of banned sub-
stances in sport. Such programs have been designed and
implemented with the dual objectives of ensuring fair
sport competition and protecting the health of athletes.
There are numerous key stakeholders in an effective
antidoping program, including athletic governing
bodies, athletic league directors and administrators,
healthcare professionals, athletic trainers, coaches, and
athletes themselves. Collectively, this group should
work to promote awareness about the consequences of
the use of performance-enhancing drugs and substances
(education), design and implement transparent and
evidence-based drug testing protocols (detection), impart
and uphold fair sanctions for athletes who abuse
performance-enhancing drugs and substances (enforce-
ment), and provide resources for athletes who develop
medical or psychiatric complications (treatment).
Athletic governing organizations play a crucial role in
the effort to curb abuse of performance-enhancing drugs
and substances among athletes. Historically, these or-
ganizations were created to generate and maintain
lists of prohibited substances and to develop policies for
the detection and punishment of users (1,2). These
fundamental objectives remain their primary focus.
The antidoping organization community now includes
members at the international, regional, national, and
local levels. Over the past decade, their role
has expanded to include development of widespread
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2431educational campaigns, support of scientiﬁc research
focused on abuse, certiﬁcation of clinical laboratories for
testing, arbitration of complex cases with disputed
athlete culpability, oversight of therapeutic use exemp-
tions, and the creation of novel abuse detection strate-
gies, including biological passports. Athletic governing
bodies should continue to revise and update lists of
banned substances as new agents become available.
These lists should be published in easily accessible pla-
ces, should be constructed in language that can be
interpreted by stakeholders from all backgrounds, and
should include known medical and psychological com-
plications of use.
Athletes of all ages and across all competition levels
should be educated with guidance from physicians and
relevant athletic organizations regarding the risks of illicit
drugs. This includes life-threatening consequences such
as sudden death with cocaine use (11). The use of
performance-enhancing drugs and substances such as
anabolic-androgenic steroids, growth hormone, and red
cell boosting agents, as well as medications such as
diuretic agents, b2-adrenergic agonists, and glucocorti-
coids, may jeopardize athletic eligibility. Use of these
drugs and substances, including many commercially
available nutritional supplements, can be harmful and
result in athletic disqualiﬁcation. Athletes should disclose
all prescription medication and supplement use to
healthcare providers and governing organizations such
that therapeutic use exemptions can be arranged when
and if necessary.
A therapeutic use exemption is an ofﬁcial authorization
from a governing agency that indicates that an athlete
may take a prescription medication that is otherwise
considered a banned substance without jeopardizing
athletic eligibility. The international standard for the
therapeutic exemption process was created in 2004 by the
World Anti-Doping Agency and is updated on a regular
basis (12). At the present time, national governing
agencies are responsible for all aspects of the therapeutic
drug exemption application and granting process. This is
contingent on 3 key criteria: 1) The athlete would expe-
rience signiﬁcant health problems without taking the
prohibited substance or method; 2) the therapeutic use of
the substance would not produce signiﬁcant enhance-
ment of performance; and 3) there is no reasonable ther-
apeutic alternative to the use of the otherwise prohibited
substance or method. The US Anti-Doping Agency pro-
vides an algorithm for determining an individual athlete’s
need for a therapeutic drug exemption based on the
competition level and the medication in question (12).
All U.S. athletes are required to submit applications
through the U.S. Anti-Doping Agency. Medications in
routine clinical practice that most frequently prompt
the need for therapeutic drug exemption includeb2-adrenergic agonists, glucocorticoids, stimulants (in-
cluding methylphenidate), and b2-adrenergic blockers.
Appropriate therapeutic drug exemption use requires a
collaborative approach between the athlete, clinician, and
appropriate governing body. It is the athlete’s respon-
sibility to ﬁle an application for a therapeutic drug
exemption if he or she is taking a banned medication.
Clinicians play a crucial role in this process, because they
must justify the necessity of the medication in question
and the absence of comparable alternatives.
Athletes considering the use of banned or unregulated
substances should be aware that the efﬁcacy and safety of
most agents have not been assessed in rigorous scientiﬁc
fashion. Athletes should not ingest any substances in an
attempt to improve performance or expedite recovery
from injury or training unless prescribed by a healthcare
professional who abides by governing organization
recommendations.
Healthcare providers should recognize that
performance-enhancing drug and substance abuse is a
potential issue with each athlete encountered. This ap-
plies to asymptomatic athletes evaluated during health
screening visits and those presenting with symptoms that
suggest occult performance-enhancing drug and sub-
stance use. An essential element of the comprehensive
clinical encounter with an athlete includes careful and
direct questioning about performance-enhancing drug
and substance use. Providers are encouraged to ask about
access to and use of common agents by name and to
counsel patients about the known and uncertain medical
consequences of abuse. It is the responsibility of all cli-
nicians who care for athletes to know which prescribed
medications have been included on banned substance
lists and to support an athlete’s therapeutic exemption
application when appropriate. Clinicians who discover
performance-enhancing drug and substance abuse should
counsel patients about the necessity of abstinence, treat
all attendant medical complications, and refer the patient
to specialists, including addiction counselors, sport psy-
chologists, and medical subspecialists as deemed appro-
priate on a case-by-case basis.
Recommendations
1. Athletes should have their nutritional needs met
through a healthy, balanced diet without dietary
supplements (Class I; Level of Evidence C).
2. As a matter of general policy, the use of performance-
enhancing drugs and supplements should be
prohibited by schools, universities, and other spon-
soring/participating organizations as a condition for
continued participation in athletic activities (Class I;
Level of Evidence C).
3. The principle of “unreasonable risk” (the potential for
risk in the absence of deﬁned beneﬁt) should be the
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2432standard for banning or recommending avoidance of
substances being evaluated for use by athletes (Class I;
Level of Evidence C).
4. Prohibited stimulants and other medications should
be subject to exceptions based on a speciﬁc medi-
cal beneﬁt, such as a b2-adrenergic blocker or a
bronchodilator. Medical need should be determined
by a treating physician on a case-by-case basis andWriting Group Disclosures
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